Tianjin Development (00882): Lisheng Pharmaceutical Forecasts 2025 Net Profit of RMB4 Billion to RMB4.4 Billion, Up 116.77%-138.44%

Stock News01-23

Tianjin Development (00882) announced that its indirectly held non-wholly owned subsidiary, Tianjin Lisheng Pharmaceutical Company Ltd. (Lisheng Pharmaceutical), is projected to achieve a net profit attributable to shareholders of the listed company ranging from RMB4 billion to RMB4.4 billion for the 2025 fiscal year. This represents a significant increase of 116.77% to 138.44% compared to the profit of RMB1.85 billion recorded in the same period last year.

During the reporting period, the net profit after deducting non-recurring gains and losses is expected to be between RMB1.6 billion and RMB1.9 billion, up 55.34% to 84.47% from the previous year's figure of RMB1.03 billion. The basic earnings per share are forecasted to be in the range of RMB1.50 per share to RMB1.80 per share.

Throughout the reporting period, the company persistently intensified its market expansion efforts, leading to an improvement in product sales. Furthermore, the net profit attributable to shareholders of the listed company registered a substantial year-on-year increase, partly influenced by dividend income from Tianshili Biopharmaceutical Industry Group Co., Ltd.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1137353713?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-23 18:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137353713","market":"sg","top_or_hot":-1,"title":"Tianjin Development (00882): Lisheng Pharmaceutical Forecasts 2025 Net Profit of RMB4 Billion to RMB4.4 Billion, Up 116.77%-138.44%","media":"Stock News","content":"<p>Tianjin Development (00882) announced that its indirectly held non-wholly owned subsidiary, Tianjin Lisheng Pharmaceutical Company Ltd. (Lisheng Pharmaceutical), is projected to achieve a net profit attributable to shareholders of the listed company ranging from RMB4 billion to RMB4.4 billion for the 2025 fiscal year. This represents a significant increase of 116.77% to 138.44% compared to the profit of RMB1.85 billion recorded in the same period last year.</p>\n<p>During the reporting period, the net profit after deducting non-recurring gains and losses is expected to be between RMB1.6 billion and RMB1.9 billion, up 55.34% to 84.47% from the previous year's figure of RMB1.03 billion. The basic earnings per share are forecasted to be in the range of RMB1.50 per share to RMB1.80 per share.</p>\n<p>Throughout the reporting period, the company persistently intensified its market expansion efforts, leading to an improvement in product sales. Furthermore, the net profit attributable to shareholders of the listed company registered a substantial year-on-year increase, partly influenced by dividend income from Tianshili Biopharmaceutical Industry Group Co., Ltd.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tianjin Development (00882): Lisheng Pharmaceutical Forecasts 2025 Net Profit of RMB4 Billion to RMB4.4 Billion, Up 116.77%-138.44%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTianjin Development (00882): Lisheng Pharmaceutical Forecasts 2025 Net Profit of RMB4 Billion to RMB4.4 Billion, Up 116.77%-138.44%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-23 18:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tianjin Development (00882) announced that its indirectly held non-wholly owned subsidiary, Tianjin Lisheng Pharmaceutical Company Ltd. (Lisheng Pharmaceutical), is projected to achieve a net profit attributable to shareholders of the listed company ranging from RMB4 billion to RMB4.4 billion for the 2025 fiscal year. This represents a significant increase of 116.77% to 138.44% compared to the profit of RMB1.85 billion recorded in the same period last year.</p>\n<p>During the reporting period, the net profit after deducting non-recurring gains and losses is expected to be between RMB1.6 billion and RMB1.9 billion, up 55.34% to 84.47% from the previous year's figure of RMB1.03 billion. The basic earnings per share are forecasted to be in the range of RMB1.50 per share to RMB1.80 per share.</p>\n<p>Throughout the reporting period, the company persistently intensified its market expansion efforts, leading to an improvement in product sales. Furthermore, the net profit attributable to shareholders of the listed company registered a substantial year-on-year increase, partly influenced by dividend income from Tianshili Biopharmaceutical Industry Group Co., Ltd.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"","article_id":"1137353713","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137353713","pubTimestamp":1769163144,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Tianjin Development (00882) announced that its indirectly held non-wholly owned subsidiary, Tianjin Lisheng Pharmaceutical Company Ltd. (Lisheng Pharmaceutical), is projected to achieve a net profit...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0028":"国家队","BK1232":"复合型公用事业","BK0239":"医药制造","002393":"力生制药","BK0188":"融资融券","00882":"天津发展"},"translate_title":"天津发展（00882）：力生制药预计2025年净利润40亿元至44亿元，增长116.77%-138.44%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002393":1,"00882":1},"content_text":"Tianjin Development (00882) announced that its indirectly held non-wholly owned subsidiary, Tianjin Lisheng Pharmaceutical Company Ltd. (Lisheng Pharmaceutical), is projected to achieve a net profit attributable to shareholders of the listed company ranging from RMB4 billion to RMB4.4 billion for the 2025 fiscal year. This represents a significant increase of 116.77% to 138.44% compared to the profit of RMB1.85 billion recorded in the same period last year.\nDuring the reporting period, the net profit after deducting non-recurring gains and losses is expected to be between RMB1.6 billion and RMB1.9 billion, up 55.34% to 84.47% from the previous year's figure of RMB1.03 billion. The basic earnings per share are forecasted to be in the range of RMB1.50 per share to RMB1.80 per share.\nThroughout the reporting period, the company persistently intensified its market expansion efforts, leading to an improvement in product sales. Furthermore, the net profit attributable to shareholders of the listed company registered a substantial year-on-year increase, partly influenced by dividend income from Tianshili Biopharmaceutical Industry Group Co., Ltd.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1137353713","isCrawlerRequest":true}